TuHURA BIOSCIENCES, INC./NV Derivative Assets (Liabilities), at Fair Value, Net
TuHURA BIOSCIENCES, INC./NV (HURA) had Derivative Assets (Liabilities), at Fair Value, Net of $0 as of 2020-03-31, per its 10-Q filed 2020-05-13.
Discontinued › Notes › Summary of Derivative Instruments
us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet · last filed 2020-05-13
- 2020-03-31: Derivative Assets (Liabilities), at Fair Value, Net $0.00.
- 2019-12-31: Derivative Assets (Liabilities), at Fair Value, Net $0.00.
- 2019-06-30: Derivative Assets (Liabilities), at Fair Value, Net $0.00.
| Period end | Derivative Assets (Liabilities), at Fair Value, Net |
|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-13 |
| 2019-12-31 | $0.00 10-Q · filed 2020-02-13 |
| 2019-06-30 | $0.00 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |